Radek Spisek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12096277/publications.pdf

Version: 2024-02-01

100 papers	8,431 citations	66234 42 h-index	54797 84 g-index
101 all docs	101 docs citations	101 times ranked	11367 citing authors

#	Article	IF	Citations
1	Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. , 2022, 10, e003190.		16
2	Efficacy and Safety of Autologous Dendritic Cellâ€"Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2022, 8, 546.	3.4	32
3	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends in Cancer, 2022, 8, 426-444.	3.8	13
4	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. Clinical Cancer Research, 2022, 28, 3053-3065.	3.2	26
5	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology, 2022, 11, .	2.1	54
6	Calreticulin and cancer. Cell Research, 2021, 31, 5-16.	5.7	174
7	Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial. Cancer Treatment and Research Communications, 2021, 28, 100427.	0.7	5
8	The cytokine milieu compromises functional capacity of tumor-infiltrating plasmacytoid dendritic cells in HPV-negative but not in HPV-positive HNSCC. Cancer Immunology, Immunotherapy, 2021, 70, 2545-2557.	2.0	9
9	Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling. Journal of Controlled Release, 2021, 332, 563-580.	4.8	11
10	Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. Gynecologic Oncology, 2021, 162, 652-660.	0.6	17
11	Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral blood. Methods in Enzymology, 2020, 631, 277-287.	0.4	0
12	Methods to assess DC-dependent priming of T cell responses by dying cells. Methods in Enzymology, 2020, 632, 55-65.	0.4	1
13	Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death and Disease, 2020, 11, 1013.	2.7	466
14	Immunological Network in Head and Neck Squamous Cell Carcinomaâ€"A Prognostic Tool Beyond HPV Status. Frontiers in Oncology, 2020, 10, 1701.	1.3	18
15	Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype. Immunology Letters, 2020, 219, 46-53.	1.1	14
16	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology, 2020, 9, 1703449.	2.1	156
17	Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. Methods in Enzymology, 2020, 632, 15-25.	0.4	3
18	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610

#	Article	IF	Citations
19	Myeloid - derived suppressor cells in Type 1 diabetes are an expanded population exhibiting diverse T-cell suppressor mechanisms. PLoS ONE, 2020, 15, e0242092.	1.1	9
20	Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Haematologica, 2020, 105, 1868-1878.	1.7	32
21	Title is missing!. , 2020, 15, e0242092.		0
22	Title is missing!. , 2020, 15, e0242092.		0
23	Title is missing!. , 2020, 15, e0242092.		0
24	Title is missing!. , 2020, 15, e0242092.		0
25	Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells. , 2019, 7, 261.		82
26	Tumour devascularisation as a potential immunotherapeutic strategy. OncoImmunology, 2019, 8, e1526614.	2.1	0
27	TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clinical Cancer Research, 2019, 25, 4820-4831.	3.2	71
28	Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications. Frontiers in Immunology, 2019, 10, 2393.	2.2	92
29	Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. , 2019, 7, 312.		52
30	High hydrostatic pressure in cancer immunotherapy and biomedicine. Biotechnology Advances, 2018, 36, 577-582.	6.0	26
31	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. OncoImmunology, 2018, 7, e1433982.	2.1	38
32	Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer. Cancer Immunology, Immunotherapy, 2018, 67, 89-100.	2.0	36
33	Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer. Immunology Letters, 2018, 193, 25-34.	1.1	36
34	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
35	Trial Watch: Toll-like receptor agonists in cancer immunotherapy. OncoImmunology, 2018, 7, e1526250.	2.1	172
36	Trial watch: Peptide-based vaccines in anticancer therapy. OncoImmunology, 2018, 7, e1511506.	2.1	121

#	Article	IF	Citations
37	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology, 2018, 7, e1503032.	2.1	67
38	Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1. Oral Oncology, 2018, 82, 75-82.	0.8	13
39	RNA-seq of macrophages of amoeboid or mesenchymal migratory phenotype due to specific structure of environment. Scientific Data, 2018, 5, 180198.	2.4	13
40	Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells. OncoImmunology, 2017, 6, e1311433.	2.1	47
41	High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy. Immunology Letters, 2017, 187, 27-34.	1.1	20
42	Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice. OncoImmunology, 2017, 6, e1362528.	2.1	15
43	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	2.1	62
44	Case-Control Study: Smoking History Affects the Production of Tumor Antigenâ€“Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Diseaseâ€“Free Group. Journal of Thoracic Oncology, 2017, 12, 249-257.	0.5	11
45	Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. OncoImmunology, 2017, 6, e1258505.	2.1	30
46	Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. PLoS ONE, 2017, 12, e0171539.	1.1	26
47	Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood, 2016, 128, 3113-3124.	0.6	107
48	Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. International Journal of Oncology, 2016, 48, 953-964.	1.4	33
49	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology, 2016, 5, e1214790.	2.1	64
50	Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients. OncoImmunology, 2016, 5, e1102827.	2.1	35
51	Trial Watchâ€”Immunostimulation with cytokines in cancer therapy. OncoImmunology, 2016, 5, e1115942.	2.1	52
52	Trial Watchâ€”Oncolytic viruses and cancer therapy. OncoImmunology, 2016, 5, e1117740.	2.1	88
53	Trial Watchâ€”Small molecules targeting the immunological tumor microenvironment for cancer therapy. OncoImmunology, 2016, 5, e1149674.	2.1	46
54	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. OncoImmunology, 2016, 5, e1088631.	2.1	104

#	Article	IF	Citations
55	Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines. Oncotarget, 2016, 7, 46120-46126.	0.8	29
56	Immunotherapy for prostate cancer. Urologie Pro Praxi, 2016, 17, 159-166.	0.0	0
57	Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Frontiers in Immunology, 2015, 6, 402.	2.2	135
58	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 588.	2.2	317
59	Combinatorial Strategies for the Induction of Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 187.	2.2	289
60	Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. OncoImmunology, 2015, 4, e965570.	2.1	189
61	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology, 2015, 4, e1008814.	2.1	102
62	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology, 2015, 4, e1008866.	2.1	237
63	Trial Watch: Adoptive cell transfer for oncological indications. OncoImmunology, 2015, 4, e1046673.	2.1	29
64	Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology, 2015, 4, e1026531.	2.1	26
65	Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget, 2015, 6, 18192-18205.	0.8	111
66	NF-ÎºB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment. Oncotarget, 2015, 6, 14123-14138.	0.8	58
67	Bordetella Adenylate Cyclase Toxin Differentially Modulates Toll-Like Receptor-Stimulated Activation, Migration and T Cell Stimulatory Capacity of Dendritic Cells. PLoS ONE, 2014, 9, e104064.	1.1	22
68	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
69	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	2.1	686
70	Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. OncoImmunology, 2014, 3, e968434.	2.1	160
71	Trial watch: Dendritic cell-based anticancer therapy. OncoImmunology, 2014, 3, e963424.	2.1	62
72	High hydrostatic pressure induces immunogenic cell death in human tumor cells. International Journal of Cancer, 2014, 135, 1165-1177.	2.3	151

#	Article	IF	Citations
73	Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients. Clinical Immunology, 2014, 153, 49-55.	1.4	17
74	Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs. Immunology Letters, 2014, 160, 39-49.	1.1	8
75	Dynamics of Tâ€cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory Tâ€cells. International Journal of Cancer, 2013, 132, 1070-1079.	2.3	89
76	Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: Their relationship to KRAS mutational status and disease recurrence. Human Immunology, 2011, 72, 1022-1028.	1.2	42
77	Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. Journal of Translational Medicine, 2011, 9, 223.	1.8	38
78	Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response. Cancer Research, 2011, 71, 4821-4833.	0.4	355
79	Intensive physical activity increases peripheral blood dendritic cells. Cellular Immunology, 2010, 266, 40-45.	1.4	25
80	Kinetics of dendritic cells reconstitution and costimulatory molecules expression after myeloablative allogeneic haematopoetic stem cell transplantation: Implications for the development of acute graft-versus host disease. Clinical Immunology, 2009, 131, 60-69.	1.4	25
81	FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clinical Immunology, 2009, 131, 1-10.	1.4	36
82	Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clinical Immunology, 2009, 133, 69-77.	1.4	79
83	Impact of Tumour Cell Death on the Activation of Anti-tumour Immune Response. , 2009, , 347-370.		1
84	Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood, 2008, 112, 1308-1316.	0.6	136
85	Towards a Better Way to Die with Chemotherapy: Role of Heat Shock Protein Exposure on Dying Tumor Cells. Cell Cycle, 2007, 6, 1962-1965.	1.3	59
86	Frequent and specific immunity to the embryonal stem cellâ€“associated antigen SOX2 in patients with monoclonal gammopathy. Journal of Experimental Medicine, 2007, 204, 831-840.	4.2	175
87	Impaired Toll-like receptor 8â€“mediated IL-6 and TNF-Î± production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood, 2007, 109, 2553-2556.	0.6	80
88	Bortezomib enhances dendritic cell (DC)â€“mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood, 2007, 109, 4839-4845.	0.6	348
89	Kinetics of Toll-like receptor-4 splice variants expression in lipopolysaccharide-stimulated antigen presenting cells of healthy donors and patients with cystic fibrosis. Microbes and Infection, 2007, 9, 1359-1367.	1.0	40
90	In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients. Clinical Immunology, 2007, 122, 18-27.	1.4	16

#	Article	IF	Citations
91	Immunoprevention of cancer: time to reconsider timing of vaccination against cancer. Expert Review of Anticancer Therapy, 2006, 6, 1689-1691.	1.1	6
92	Immunoprevention of Cancer. Hematology/Oncology Clinics of North America, 2006, 20, 735-750.	0.9	12
93	Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease. Transfusion, 2006, 46, 55-65.	0.8	65
94	Combined CNS and pituitary involvement as a primary manifestation of Wegener granulomatosis. Clinical Rheumatology, 2006, 25, 739-742.	1.0	24
95	Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clinical Immunology, 2006, 120, 260-271.	1.4	140
96	Gliadin Fragments Induce Phenotypic and Functional Maturation of Human Dendritic Cells. Journal of Immunology, 2005, 175, 7038-7045.	0.4	94
97	Differential Antigenic Targets of Anti-Tumor Immune Response and Selective Immunity to Stem Cell Associated Group B SOX Proteins in Preneoplastic Versus Malignant Gammopathy.. Blood, 2005, 106, 5116-5116.	0.6	0
98	Maturation of dendritic cells by bacterial immunomodulators. Vaccine, 2004, 22, 2761-2768.	1.7	42
99	Transient exposure of dendritic cells to maturation stimuli is sufficient to induce complete phenotypic maturation while preserving their capacity to respond to subsequent restimulation. Cancer Immunology, Immunotherapy, 2003, 52, 445-454.	2.0	27
100	Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunology, Immunotherapy, 2001, 50, 417-427.	2.0	81